Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 16/20 | 0.78 |
| ▸ | CLK3 | P49761 | 16/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 16/20 | 0.78 |
| ▸ | ITK | Q08881 | 1/20 | 0.63 |
| ▸ | WNT1 | P04628 | 2/20 | 0.62 |
| ▸ | CDK7 | P50613 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18448271 | 0.93 | CLK2 (0.77) | CLK2CLK3DYRK1AITKWNT1 | |
| SCHEMBL18446680 | 0.93 | CLK2 (0.74) | CLK2CLK3DYRK1AITKWNT1 | |
| SCHEMBL18437174 | 0.90 | CLK2 (0.77) | CLK2CLK3DYRK1AITKWNT1 | |
| SCHEMBL18441313 | 0.89 | CLK2 (0.75) | CLK2CLK3DYRK1AITKWNT1 | |
| SCHEMBL18440126 | 0.88 | CLK2 (1.00) | CLK2CLK3DYRK1AITKWNT1 | |
| SCHEMBL18486888 | 0.87 | CLK2 (0.86) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL18444193 | 0.87 | CLK2 (1.00) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL18451399 | 0.87 | CLK2 (0.77) | CLK2CLK3DYRK1AITK | |
| SCHEMBL20455121 | 0.86 | CLK2 (1.00) | CLK2CLK3DYRK1AWNT1CDK7 | |
| SCHEMBL18448443 | 0.85 | CLK3 (0.87) | CLK2CLK3DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463651-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-11-05 | — | — | US | claimed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | claimed |
| WO-2017024010-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-10463651-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| WO-2017024010-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463651-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 788/4885CLK3 683/4885DYRK1A 545/4885 |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 788/4885CLK3 683/4885DYRK1A 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.